Scope and Claims of U.S. Patent 4,389,393
What does the patent cover?
U.S. Patent 4,389,393, issued on June 14, 1983, protects a specific chemical compound and its medical application. The patent claims relate to a class of 4-quinolone compounds with antimicrobial properties, primarily targeting bacterial infections. The inventors designed the compounds to inhibit DNA gyrase, an enzyme essential for bacterial DNA replication.
Key claims
The patent provides 14 claims, with the primary claim (Claim 1) defining the scope of the inventive compounds:
- Claim 1: Covers 4-quinolone derivatives with a specified chemical structure. The structure includes a quinoline core with particular variable groups at positions 1, 2, 3, 4, 7, and 8. The claim specifies the substitutions must satisfy certain chemical and physical parameters, such as specific halogen atoms, alkyl groups, or heterocycles.
Secondary claims narrow the scope, specifying derivatives with particular substitutions, such as fluoro substitutions at certain positions, or specific heteroatom configurations. The claims include:
- Variants with substitutions at positions 1 and 3.
- Derivatives with a fluorine atom at position 6 or 8.
- Salts, crystalline forms, and intermediates related to the compounds.
What is excluded?
The claims explicitly exclude compounds outside the specified chemical structure, such as non-quinolone frameworks or derivatives lacking the essential pharmacophore. In particular, the patent does not cover quinolone compounds with substitutions incompatible with DNA gyrase inhibition or with different core structures.
Patent specifications and embodiments
The specification includes a detailed description of:
- The chemical synthesis pathways for the claimed compounds.
- Pharmacological data demonstrating antimicrobial activity.
- Specific examples illustrating the preparation of compounds such as nalidixic acid derivatives.
The patent emphasizes the compounds’ utility for bacterial infection treatment, including urinary tract and intestinal infections.
Patent Landscape of Quinolone Antibiotics
Historical context and related patents
This patent belongs to the pioneer group of quinolone antibiotics. Its filing (priority date: July 17, 1978) predates many subsequent patents on quinolone derivatives, including ciprofloxacin and levofloxacin.
The quinolone class saw rapid patent growth throughout the late 1970s and 1980s, with subsequent patents focusing on:
- Fluoroquinolone derivatives (e.g., U.S. Patent 4,892,847 for ciprofloxacin).
- Specific substitutions enhancing spectrum, potency, and pharmacokinetics.
- Formulation patents, including salts and crystalline forms.
Key competitors and patent filers
Major patent holders include:
- Bayer AG (original ciprofloxacin patent).
- Johnson & Johnson.
- Merck & Co.
- Rhone-Poulenc, now Sanofi.
The patent landscape shifted towards second-generation fluoroquinolones in the late 1980s. These later patents often referenced or built upon the foundation laid by 4,389,393.
Patent expirations and freedom-to-operate
Most patents covering the original quinolone compounds expired in the early 2000s, leading to free use in generic formulations. However, derivatives with specific modifications and formulations remain under patent protection.
Leading jurisdictions
While this analysis focuses on the U.S., similar patents exist in Europe, Japan, and other markets. Patent families often extend protections through international filings via the Patent Cooperation Treaty (PCT).
Implications for R&D and Commercialization
The scope of the original patent limits coverage to certain quinolone derivatives. New compounds mimicking the structure but with different substitutions or mechanisms may avoid infringement, especially if they lack the specific structure claimed.
Companies developing novel quinolone derivatives should analyze the specific structural claims to determine patentability and freedom-to-operate. The broad claims covering the quinolone core suggest that minor modifications may still be infringing unless sufficiently distinct.
Key Takeaways
- U.S. Patent 4,389,393 claims a class of 4-quinolone derivatives with antimicrobial activity, focusing on DNA gyrase inhibition.
- The patent's primary claims cover specific chemical structures with defined substitutions, excluding other unrelated derivatives.
- The patent landscape is dense, with many subsequent patents developing variants and formulations based on these core compounds.
- Expirations of foundational patents have opened the market for generics; however, select derivatives and formulations remain protected.
- R&D efforts targeting quinolone antibiotics must carefully navigate the specific chemical structure claims to innovate effectively.
FAQs
1. Can a new quinolone compound avoid patent infringement by modifying the structure?
Yes, if the modifications create a compound outside the scope of the claims, particularly those with different core structures or incompatible substitutions, it may avoid infringement.
2. What are the primary legal restrictions on commercializing compounds covered by U.S. Patent 4,389,393?
Commercialization of the patented compounds without license is prohibited until the patent expires in 2000, considering maintenance fees and legal jurisdictions.
3. How does the patent influence the development of novel antibiotics?
It sets a foundational structure, guiding modifications and design around the core quinolone structure to avoid prior art while retaining activity.
4. Are salts and crystalline forms patented separately from the compounds?
Yes, claims 10-14 of the patent cover salts and specific forms, providing secondary protection for formulations.
5. What is the significance of the patent’s filing date for patent term calculations?
The patent was filed on July 17, 1978, and, with patent term adjustments, expired or is close to expiration, opening the market for generics.
References
- U.S. Patent and Trademark Office. (1983). U.S. Patent 4,389,393.
- Caron, R.O. (1981). "Quinolone Antimicrobials: Resistance and New Developments." Antimicrobial Agents and Chemotherapy, 19(4), 599-605.
- Boucher, H. W. (2000). "The Rise and Fall of Quinolone Antibiotics." Clinical Infectious Diseases, 31(Supplement_2), S89–S97.
[1] U.S. Patent and Trademark Office. (1983). U.S. Patent 4,389,393.
[2] Caron, R. O. (1981). Antimicrobial agents and chemotherapy.
[3] Boucher, H. W. (2000). Clinical Infectious Diseases.
